Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

HUMA

Humacyte Inc

Sep 27 • 04:00PM ET

5.58

Dollar change +0.11
Percentage change 2.01	%

Healthcare • Biotechnology • USA • NASD

Held by: XBI VTI IWM VXF IWO IBB SCHA VTWO VHT LABU

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.26	Insider Own	21.88%	Shs Outstand	103.67M	Perf Week	7.31%
Market Cap	666.98M	Forward P/E	-	EPS next Y	-0.86	Insider Trans	-18.77%	Shs Float	93.38M	Perf Month	-13.49%
Income	-139.66M	PEG	-	EPS next Q	-0.25	Inst Own	25.89%	Short Float	15.00%	Perf Quarter	16.25%
Sales	0.00M	P/S	-	EPS this Y	-12.91%	Inst Trans	-9.27%	Short Ratio	4.26	Perf Half Y	79.42%
Book/sh	-0.24	P/B	-	EPS next Y	29.10%	ROA	-91.17%	Short Interest	14.01M	Perf Year	88.51%
Cash/sh	0.78	P/C	7.13	EPS next 5Y	-	ROE	-850.81%	52W Range	1.96 - 9.97	Perf YTD	96.48%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-44.03%	Beta	1.46
Dividend TTM	-	Quick Ratio	5.41	Sales past 5Y	0.00%	Gross Margin	-26519.35%	52W Low	184.69%	ATR (14)	0.48
Dividend Ex-Date	-	Current Ratio	5.41	EPS Y/Y TTM	-47.10%	Oper. Margin	0.00%	RSI (14)	46.60	Volatility	9.44% 7.77%
Employees	183	Debt/Eq	-	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.33	Target Price	13.17
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-116.43%	Payout	-	Rel Volume	0.42	Prev Close	5.47
Sales Surprise	-	EPS Surprise	-101.34%	Sales Q/Q	-	Earnings	Aug 13 BMO	Avg Volume	3.29M	Price	5.58
SMA20	0.96%	SMA50	-16.33%	SMA200	13.35%	Trades		Volume	1,375,796	Change	2.01%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-23	Initiated	H.C. Wainwright	Buy	$6
Aug-14-23	Upgrade	Piper Sandler	Underweight → Neutral	$2.75 → $3.50
Jun-22-23	Initiated	Cantor Fitzgerald	Overweight	$6
May-16-22	Downgrade	Piper Sandler	Overweight → Underweight	$10 → $4
Oct-29-21	Initiated	Cowen	Outperform	$17
Sep-24-21	Initiated	Oppenheimer	Outperform	$16
Sep-22-21	Initiated	BTIG Research	Buy	$19
Sep-16-21	Initiated	Piper Sandler	Overweight	$17

Sep-26-24 05:26PM	Humacyte to Host Virtual KOL Event to Discuss Case Studies on the Use of Acellular Tissue Engineered Vessel (ATEV ) in Vascular Trauma Treatment on September 30, 2024 (GlobeNewswire)
Sep-19-24 08:00AM	Humacyte Announces Allowance of U.S. Patent Covering BioVascular Pancreas (BVP ) (GlobeNewswire)
Sep-03-24 08:00AM	Humacyte to Participate at Upcoming Investor Conferences in September (GlobeNewswire) -8.51%
Aug-27-24 08:00AM	Humacyte Presents Positive Long-Term Results of ATEV in Treatment of Vascular Trauma in Military Setting from Ukraine Humanitarian Program (GlobeNewswire) -5.53%
Aug-13-24 07:00AM	Humacyte Second Quarter 2024 Financial Results and Business Update (GlobeNewswire)
08:00AM	Loading…
Aug-12-24 08:00AM	Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024 (GlobeNewswire) -16.37%
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Aug-09-24 04:05PM	Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV) BLA for the Treatment of Vascular Trauma (GlobeNewswire)
Jul-31-24 07:00AM	Humacyte Acellular Tissue Engineered Vessel (ATEV ) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis (GlobeNewswire) +15.37%
Jul-16-24 08:00AM	Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones (GlobeNewswire)
Jul-09-24 10:07AM	Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs (Business Wire)
Jul-01-24 08:00AM	Humacyte Acellular Tissue Engineered Vessel (ATEV ) Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD) (GlobeNewswire) +11.87%
Jun-25-24 08:00AM	Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP ) Program (GlobeNewswire)
Jun-17-24 08:00AM	Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte's Human Acellular Vessel (HAV ) (GlobeNewswire) -12.20%
Jun-03-24 07:01PM	Insider Sale: COO Heather Prichard Divests All Shares in Humacyte Inc (HUMA) (GuruFocus.com) -9.50%
08:00AM	Loading…
May-30-24 08:00AM	Humacyte to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +18.03%
May-16-24 02:20PM	Hedge Fund and Insider Trading News: Michael Burry, Leon Cooperman, Ray Dalio, Stanley Druckenmiller, Millennium Management, Paulson & Co, Rokos Capital Management, Humacyte Inc (HUMA), GeneDx Holdings Corp. (WGS), and More (Insider Monkey)
May-13-24 08:00AM	Humacyte to Participate at Upcoming Investor Conferences in May (GlobeNewswire) +16.60%
May-10-24 02:43PM	Humacyte Inc (HUMA) Q1 2024 Earnings: Aligns with Analyst Projections Amid Strategic Advances (GuruFocus.com)
11:54AM	HUMA Stock Earnings: Humacyte Misses EPS for Q1 2024 (InvestorPlace)
07:00AM	Humacyte First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
May-06-24 08:00AM	Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 10, 2024 (GlobeNewswire)
Apr-21-24 08:39AM	10 Stocks American Politicians are Buying in 2024 (Insider Monkey)
Mar-26-24 04:05PM	Humacyte to Host Virtual KOL Event Hemodialysis Access: A Crossroads of Care, on March 28, 2024 (GlobeNewswire)
Mar-23-24 10:16AM	Humacyte, Inc. (NASDAQ:HUMA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-22-24 11:53AM	HUMA Stock Earnings: Humacyte Meets EPS for Q4 2023 (InvestorPlace) -8.06%
07:00AM	Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update (GlobeNewswire)
Mar-19-24 08:58AM	Should You Buy Humacyte (HUMA) Ahead of Earnings? (Zacks)
Mar-18-24 08:00AM	Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024 (GlobeNewswire) +8.33%
Mar-01-24 09:16AM	Humacyte, Inc. to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -25.52%
09:18PM	Loading…
Feb-29-24 09:18PM	Humacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common Stock (GlobeNewswire)
04:01PM	Humacyte, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Feb-12-24 09:13AM	Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma (Zacks) +6.61%
Feb-09-24 08:00AM	Human Acellular Vessel (HAV ) Biologics License Application Granted Priority Review by U.S. FDA for the Treatment of Vascular Trauma (GlobeNewswire) +15.79%
Dec-12-23 08:00AM	Humacyte Submits Biologics License Application (BLA) to U.S. FDA Seeking Approval of Human Acellular Vessel (HAV ) for the Treatment of Vascular Trauma (GlobeNewswire)
Nov-24-23 08:00AM	Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-17-23 08:00AM	Humacyte Announces Two Presentations at the VEITHsymposium of Positive Clinical Results of the Human Acellular Vessel (HAV ) in the Treatment of Vascular Trauma (GlobeNewswire)
Nov-14-23 08:55AM	Sidoti Events, LLCs Virtual November Micro-Cap Conference (ACCESSWIRE) +6.22%
Nov-10-23 10:33AM	Humacyte, Inc. (NASDAQ:HUMA) Q3 2023 Earnings Call Transcript (Insider Monkey) +6.33%
Nov-09-23 04:01PM	Humacyte Third Quarter 2023 Financial Results and Business Update (GlobeNewswire)
Nov-02-23 04:05PM	Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023 (GlobeNewswire) +6.03% +5.21%
Oct-16-23 08:55AM	Humacyte Publishes Preclinical Results Showing Human Acellular Vessel (HAV ) Patency as Modified Blalock Taussig Thomas Shunt in Juvenile Primate Model (GlobeNewswire)
Sep-23-23 06:15AM	'Politicians have too much power': Sen. Tommy Tuberville recently disclosed $250K in agriculture futures all while he's been influencing farming industry policies (Moneywise)
Sep-21-23 04:05PM	Humacyte to Present at the Cantor Global Healthcare Conference (GlobeNewswire)
Sep-18-23 04:05PM	Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023 (GlobeNewswire) -5.72%
Sep-12-23 07:00AM	Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel (HAV) in Treatment of Patients with Vascular Trauma (GlobeNewswire)
Sep-11-23 05:00PM	Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel (HAV) Tuesday, September 12, 2023 at 8:00 AM ET (GlobeNewswire)
08:00AM	Results From Mayo Clinic Clinical Study of Humacytes Human Acellular Vessel (HAV) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference (GlobeNewswire)
Aug-15-23 08:00AM	Humacyte Presents Clinical Performance of Human Acellular Vessel (HAV) From Ukrainian Humanitarian Program (GlobeNewswire) +10.89%
Aug-14-23 07:00AM	Humacyte Second Quarter 2023 Financial Results and Business Update (GlobeNewswire) +23.55%
Aug-07-23 08:00AM	Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 14, 2023 (GlobeNewswire)
Aug-03-23 08:00AM	Humacyte Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel (HAV) (GlobeNewswire)
Jul-26-23 08:00AM	Humacyte Completes Enrollment in Phase 2/3 Trial of Human Acellular Vessel (HAV) for Vascular Trauma Repair (GlobeNewswire)
Jun-20-23 06:35AM	Daily Vickers Top Buyers & Sellers for 06/20/2023 (Argus Research) -10.25%
Jun-05-23 04:05PM	Humacyte to Present at the Jefferies Healthcare Conference (GlobeNewswire) +5.07% +9.65%
May-12-23 07:05AM	Humacyte First Quarter 2023 Financial Results and Business Update (GlobeNewswire) -6.48%
07:00AM	Humacyte and Oberland Capital Announce Funding Arrangement Totaling Up to $160 Million (GlobeNewswire)
May-09-23 08:00AM	Humacyte Announces Publication in Lancet Regional Health - Europe Presenting Use of Human Acellular Vessel (HAV) to Treat Vascular Injuries in Ukraine (GlobeNewswire) -10.66%
07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-05-23 08:00AM	Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 12, 2023 (GlobeNewswire)
May-04-23 08:00AM	Humacytes Human Acellular Vessel (HAV) Receives FDAs Regenerative Medicine Advanced Therapy (RMAT) Designation for Urgent Arterial Repair Following Vascular Trauma (GlobeNewswire) +7.06%
May-02-23 03:30PM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE) +14.63%
Apr-28-23 08:00AM	Humacyte to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ (GlobeNewswire)
Apr-27-23 08:00AM	Humacyte, JDRF Collaborating to Develop Insulin-Producing Biovascular Pancreas to Treat Type 1 Diabetes (GlobeNewswire)
Apr-18-23 08:00AM	Humacyte Announces Publication of Preclinical Study Comparing Human Acellular Vessel (HAV) to Expanded Polytetrafluoroethylene (ePTFE) Graft in Vascular Trauma (GlobeNewswire)
Apr-11-23 08:00AM	Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel (HAV) for Hemodialysis Access in End-Stage Renal Disease Patients (GlobeNewswire) +12.61%
Mar-29-23 09:13AM	Investors in Humacyte (NASDAQ:HUMA) have unfortunately lost 56% over the last year (Simply Wall St.)
Mar-24-23 07:00AM	Humacyte Announces Fourth Quarter and Year End 2022 Financial Results and Business Update (GlobeNewswire) -5.83%
Mar-21-23 08:01AM	Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 24, 2023 (GlobeNewswire) +8.21%
Feb-27-23 07:00AM	Humacyte to Present at Upcoming Investor Conferences in March (GlobeNewswire)
Feb-07-23 07:00AM	Presenting on the Emerging Growth Conference on February 8 Register Now (GlobeNewswire)
Jan-24-23 08:00AM	Humacyte Publication in the Journal of Vascular Surgery Vascular Science Reports the Human Acellular Vessel (HAV) Remains Durable at Six Years in Patients with Peripheral Artery Disease (GlobeNewswire)
Jan-17-23 10:00AM	Sidoti's January Micro-Cap Conference (ACCESSWIRE)
Dec-13-22 08:00AM	Humacyte Hosting Key Opinion Leader Webinar on Vascular Trauma: Ukrainian Surgeons Discuss Use of Human Acellular Vessels (HAV) in Wartime (GlobeNewswire) -8.74%
Dec-06-22 07:00AM	Sidoti's December Small-Cap Virtual Conference (ACCESSWIRE) -6.79%
Dec-01-22 07:00AM	Humacyte Human Acellular Vessel (HAV) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022 (GlobeNewswire)
Nov-23-22 08:00AM	Humacyte to Present at the 34th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-10-22 07:00AM	Humacyte Third Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Nov-07-22 08:00AM	Humacyte Presents Six-Month Human Acellular Vessel (HAV) Coronary Artery Bypass Graft (CABG) Data at the American Heart Association Scientific Sessions 2022 Meeting (GlobeNewswire)
Nov-03-22 08:00AM	Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 10, 2022 (GlobeNewswire)
Sep-23-22 08:00AM	Humacyte Announces Presentations by Ukrainian Surgeons on Use of the Human Acellular Vessel to Treat Wartime Vascular Trauma at the European Society for Vascular Surgery Annual Meeting (GlobeNewswire)
Sep-20-22 08:00AM	Humacyte Expands Board of Directors and Leadership Team with New Appointments (GlobeNewswire)
Sep-09-22 08:00AM	Humacyte Announces Presentation on Investigational Human Acellular VesselTM for Treatment of Vascular Trauma at the International Committee of Military Medicine World Congress (GlobeNewswire)
Sep-08-22 08:01AM	Humacyte Presents at Multiple Conferences in September 2022 (GlobeNewswire) +8.39%
Aug-12-22 07:00AM	Humacyte Second Quarter 2022 Financial Results and Business Update (GlobeNewswire)
Aug-05-22 08:00AM	Humacyte to Present Second Quarter 2022 Financial Results and Provide Recent Corporate Update on August 12, 2022 (GlobeNewswire)
Jul-25-22 08:26PM	Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel (HAV) in Coronary Artery Bypass Grafting (CABG) Presented at American Heart Association Meeting (GlobeNewswire)
Jul-19-22 08:00AM	Humacyte Announces Presentation of Preclinical Data on the HAV in Coronary Artery Bypass Grafting at the Basic Cardiovascular Sciences Scientific Sessions (GlobeNewswire)
Jul-07-22 08:00AM	Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels in the Treatment of Vascular Trauma (GlobeNewswire) +6.30%
Jul-04-22 07:48AM	Humacyte (NASDAQ:HUMA) shareholders have endured a 68% loss from investing in the stock a year ago (Simply Wall St.)
Jun-29-22 08:00AM	Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel (HAV) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options (GlobeNewswire)
Jun-27-22 07:30AM	Humacyte Expands Board of Directors with Appointment of Diane Seimetz, Ph.D. (GlobeNewswire)
Jun-21-22 07:30AM	Humacyte Provides Update on Patients Treated at Front-Line Hospitals in Ukraine with the Human Acellular Vessel (HAV) for Repair of Vascular Trauma Injuries (GlobeNewswire)
Jun-08-22 08:00AM	Humacyte Presents New Immunogenicity Data on Human Acellular Vessels (HAVs) (GlobeNewswire)
May-16-22 08:00AM	Humacyte to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -15.08%
May-13-22 07:00AM	Humacyte First Quarter 2022 Financial Results and Business Update (GlobeNewswire) +6.55%
May-09-22 08:00AM	Humacyte to Provide Human Acellular Vessels (HAVs) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries (GlobeNewswire) -9.24%
May-06-22 08:00AM	Humacyte to Present First Quarter 2022 Financial Results and Provide Recent Corporate Update on May 13, 2022 (GlobeNewswire) -11.92%
Apr-05-22 08:00AM	Humacyte Expands Leadership Team with Appointment of Shamik Parikh, M.D., as Chief Medical Officer (GlobeNewswire)
Apr-04-22 08:00AM	Humacyte Announces Date of Annual Shareholder Meeting (GlobeNewswire)

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Green Charles Bruce	Director	Sep 13 '24	Option Exercise	4.09	1,200	4,908	2,400	Sep 16 04:36 PM
Sebelius Kathleen	Director	Sep 10 '24	Option Exercise	3.99	7,000	27,926	43,910	Sep 11 05:53 PM
Sebelius Kathleen	Director	Sep 10 '24	Sale	5.40	5,182	28,004	40,276	Sep 11 05:53 PM
Dougan Brady W	Director	Sep 10 '24	Sale	5.23	288,674	1,509,765	3,230,884	Sep 11 05:52 PM
Dougan Brady W	Director	Sep 09 '24	Sale	5.42	157,704	854,756	3,519,558	Sep 11 05:52 PM
Niklason Laura E	President, CEO and Director	Sep 10 '24	Sale	5.23	288,674	1,509,765	3,230,884	Sep 11 05:50 PM
Niklason Laura E	President, CEO and Director	Sep 09 '24	Sale	5.42	157,704	854,756	3,519,558	Sep 11 05:50 PM
AYABUDGE LLC	Director	Sep 10 '24	Proposed Sale	5.23	288,674	1,510,584		Sep 10 04:19 PM
Sebelius Kathleen	Director	Sep 10 '24	Proposed Sale	5.41	5,182	28,012		Sep 10 10:41 AM
AYABUDGE LLC	Director	Sep 09 '24	Proposed Sale	5.42	157,704	855,153		Sep 09 04:19 PM
Niklason Laura E	President, CEO and Director	Aug 29 '24	Buy	6.54	1,222	7,998	242,054	Sep 03 04:23 PM
Dougan Brady W	Director	Aug 29 '24	Buy	6.54	1,222	7,998	242,054	Sep 03 04:17 PM
Dougan Brady W	Director	Aug 29 '24	Sale	6.35	352,112	2,235,911	3,677,262	Aug 29 06:52 PM
Dougan Brady W	Director	Aug 28 '24	Sale	6.47	277,090	1,792,772	4,029,374	Aug 29 06:52 PM
Dougan Brady W	Director	Aug 27 '24	Sale	6.71	252,676	1,695,456	4,306,464	Aug 29 06:52 PM
Niklason Laura E	President, CEO and Director	Aug 29 '24	Sale	6.35	352,112	2,235,911	3,677,262	Aug 29 06:48 PM
Niklason Laura E	President, CEO and Director	Aug 28 '24	Sale	6.47	277,090	1,792,772	4,029,374	Aug 29 06:48 PM
Niklason Laura E	President, CEO and Director	Aug 27 '24	Sale	6.71	252,676	1,695,456	4,306,464	Aug 29 06:48 PM
Sander Dale A.	CFO and Chief Corp. Deve. Off.	Aug 27 '24	Option Exercise	2.56	39,389	100,836	41,389	Aug 29 06:45 PM
Sander Dale A.	CFO and Chief Corp. Deve. Off.	Aug 27 '24	Sale	6.68	39,389	263,119	2,000	Aug 29 06:45 PM
AYABUDGE LLC	Director	Aug 29 '24	Proposed Sale	6.35	352,112	2,235,911		Aug 29 04:31 PM
Ayabudge LLC	Director	Aug 28 '24	Proposed Sale	6.47	277,090	1,792,772		Aug 28 04:12 PM
Ayabudge LLC	Director	Aug 27 '24	Proposed Sale	6.71	252,676	1,696,341		Aug 27 04:41 PM
Sander Dale A.	Officer	Aug 27 '24	Proposed Sale	6.68	39,389	263,311		Aug 27 01:09 PM
Constantino Michael T.	Director	Aug 15 '24	Buy	6.29	3,100	19,494	12,350	Aug 15 04:08 PM
Sebelius Kathleen	Director	Jun 14 '24	Option Exercise	2.56	39,389	100,836	39,389	Jun 17 04:15 PM
Niklason Laura E	President, CEO and Director	Jun 11 '24	Sale	7.08	358,630	2,537,943	4,830,658	Jun 13 04:48 PM
Niklason Laura E	President, CEO and Director	Jun 12 '24	Sale	7.30	271,518	1,982,081	4,559,140	Jun 13 04:48 PM
Dougan Brady W	Director	Jun 11 '24	Sale	7.08	358,630	2,537,943	4,830,658	Jun 13 04:47 PM
Dougan Brady W	Director	Jun 12 '24	Sale	7.30	271,518	1,982,081	4,559,140	Jun 13 04:47 PM
Niklason Laura E	President, CEO and Director	Jun 04 '24	Buy	6.35	2,362	14,999	240,832	Jun 04 07:05 PM
Dougan Brady W	Director	Jun 04 '24	Buy	6.35	2,362	14,999	240,832	Jun 04 07:03 PM
Niklason Laura E	President, CEO and Director	May 31 '24	Sale	7.91	809,786	6,407,330	5,381,354	Jun 04 06:57 PM
Niklason Laura E	President, CEO and Director	Jun 03 '24	Sale	7.42	190,214	1,411,388	5,191,140	Jun 04 06:57 PM
Niklason Laura E	President, CEO and Director	Jun 04 '24	Sale	7.28	1,852	13,483	5,189,288	Jun 04 06:57 PM
Dougan Brady W	Director	May 31 '24	Sale	7.91	809,786	6,407,330	5,381,354	Jun 04 06:55 PM
Dougan Brady W	Director	Jun 03 '24	Sale	7.42	190,214	1,411,388	5,191,140	Jun 04 06:55 PM
Dougan Brady W	Director	Jun 04 '24	Sale	7.28	1,852	13,483	5,189,288	Jun 04 06:55 PM
Niklason Laura E	President, CEO and Director	Jun 03 '24	Buy	7.37	2,050	15,108	238,470	Jun 03 04:31 PM
Dougan Brady W	Director	Jun 03 '24	Buy	7.37	2,050	15,108	238,470	Jun 03 04:27 PM
Prichard Heather Ledbetter	Chief Operating Officer	May 30 '24	Option Exercise	2.75	126,945	349,544	81,404	Jun 03 04:23 PM
Prichard Heather Ledbetter	Chief Operating Officer	May 30 '24	Sale	8.14	188,886	1,536,899	2,625	Jun 03 04:23 PM
Prichard Heather Ledbetter	Chief Operating Officer	May 31 '24	Sale	9.41	2,625	24,707	0	Jun 03 04:23 PM
Wallace Max N.	Director	May 20 '24	Buy	6.25	8,005	50,030	4,015	May 21 04:08 PM
Green Charles Bruce	Director	May 20 '24	Option Exercise	4.09	600	2,454	1,200	May 21 04:08 PM
Green Charles Bruce	Director	May 17 '24	Option Exercise	4.09	600	2,454	600	May 20 04:11 PM
Binder Gordon M	Director	May 15 '24	Buy	6.78	50,000	339,000	160,000	May 15 07:24 PM
Binder Gordon M	Director	May 15 '24	Buy	6.57	50,000	328,500	50,000	May 15 07:24 PM
Dougan Brady W	Director	Oct 10 '23	Option Exercise	1.19	114,420	136,160	1,384,660	Oct 10 04:11 PM
Niklason Laura E	President, CEO and Director	Oct 10 '23	Option Exercise	1.19	114,420	136,160	1,384,660	Oct 10 04:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HUMA

Humacyte Inc

Upgrade your FINVIZ experience